Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus

Lupus

Volumn 13, Issue 11, 2004, Pages 869-876

  Merrill, J T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Anticardiolipin; Antiphospholipid; Beta2 glycoprotein I; Systemic lupus erythematosus

Indexed keywords

ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BLOOD CLOTTING; CLINICAL FEATURE; CONFUSION; DIAGNOSTIC TEST; GENETIC LINKAGE; HLA SYSTEM; HUMAN; IMMUNOREACTIVITY; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; VIRUS INFECTION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 9244228029     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2026oa     Document Type: Review

References (76)

1. Hughes GR, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheum 1986; 13: 486-489.
2. Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheum 1989; 16: 762-767.
3. Boey ML, Colaco CB, Gharavi AE et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287: 1021-1023.
4. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
5. Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-1027.
6. Lakos G, Kiss E, Regeczy N et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000; 27: 924-929.
7. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40: 1725.
9. Munoz-Rodriguez FJ, Font J, Cervera R et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999; 29: 182-190.
10. Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica 1997; 82: 101-105.
11. Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9.
12. Vivancos J, Lopez-Soto A, Font J et al. Primary antiphospholipid syndrome: clinical and biological study of 36 cases. Med Clinica 1994; 102: 561-565.
13. Mujic F, Cuadrado MJ, Lloyd M, Khamashta MA, Page G, Hughes GR. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheum 1995; 22: 1589-1592.
14. Carbone J, Orera M, Rodriguez-Mahou M et al. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus 1999; 8: 274-278.
15. Derksen RH, Gmelig-Meijling FH, de Groot PG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus 1996; 5: 77-80.
16. Aron AL, Cuellar ML, Brey RL et al. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol 1995; 101: 78-81.
17. Shibata S, Harpel P, Bona C, Fillit H. Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-antithrombin III compexes. Clin Immunol Immunopathol 1993; 67: 264-272.
18. Villarreal GM, Alarcon-Segovia D, Villa AR, Cabral AR, Shoenfeld Y. Presence of a 16/6 related human anti-DNA common idiotype [SA1] in the anticardiolipin antibodies of patients with primary antiphospholipid syndrome. J Rheum 1991; 18: 1537-1541.
19. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum 1996; 25: 414-420.
20. Wilson WA. Histocompatibility genes in antiphospholipid syndrome. Lupus 1996; 5: 259-262.
21. Domenico Sebastiani G, Minisola G, Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2003; 2: 387-394.
22. Sherson RA, Baguley E, Pal C, Hughes GR. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis 1991; 50: 805-810.
23. Davis WD, Brey RL Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheum 1992; 10: 455-460.
24. Norberg R, Nived O, Strurfeld G. Anticardiolipin and complement activation: relation to clinical symptoms. J Rheum 1987; 14: 149-153.
25. Peitsch MC, Kovacsovics TJ. Antibody-independent activation of Cl. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. J Immunol 1987; 138: 1871-1876.
26. Fukumura H, Hayoshi K, Ishikawa S. Complement-induced thrombus formation on the surface of poly[N-vinylpyrrolidone]-grafted polyethylene. Biomaterials 1987; 8: 74-79.
27. Unander AM, Norberg R, Hahn L, Arfors L. Anticardiolipin antibodies and complement in 99 women with habitual abortion. Am J Obstet Gynecol 1987; 156: 114-119.
28. Cheng HM, Yap SF. Anticardiolipin and complement. Arthritis Rheum 1988; 31: 1211-1212.
29. Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43: 28-36.
30. Ong SG, Cheng HM, Soon SC, Goh E, Chow SK, Yeap SS. IgG anti-beta(2) glycoprotein I antibodies in Malaysian patients with antiphospholipid syndrome and systemic lupus erythematosus: prevalence and clinical correlations. Clin Rheumatol 2002; 21: 382-385.
31. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
32. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-2536.
33. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford) 2003; 42: 645-651.
34. Queyrel V, Ducloy-Bouthors AS, Michon-Pasturel U et al. Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women. Rev Med Interne 2003; 24: 158-164.
35. Munoz-Rodriguez FJ, Reverter JC, Font J et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus 2002; 11: 730-735.
36. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-992.
37. Eriksson K, Peltola J, Keranen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001; 46: 129-137.
38. Brey RL, Stallworth CL, McGlasson DL et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002; 33: 2396-2400.
39. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 2001; 10: 45-50.
40. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-1764.
41. Scofield RH, Bruner GR, Kelly JA et al. Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13. Blood 2003; 101: 992-997.
42. Daugas E, Nochy D, du Huong LT et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52.
43. Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003; 12: 883-890.
44. Chapman J, Abu-Katash M, Inzelberg R et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 2002; 204: 81-84
45. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
46. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999; 78: 167-175.
47. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. Am J Roentgenol 1996; 167: 1573-1578.
48. Sanmarco M, Soler C, Christides C et al. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997; 129: 499-506.
49. Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 2003; 62: 1106-1111.
50. Schenkein HA, Berry CR, Burmeister JA et al. Anti-cardiolipin antibodies in sera from patients with periodontitis. J Dent Res 2003; 82: 919-922.
51. Von Landenberg P, Lehmann HW, Knoll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003; 48: 1939-1947.
52. Gharavi AE, Pierangeli SS, Harris EN. Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology 2003; 207: 37-42.
53. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 545-552.
54. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12: 112-116.
55. Yamada H, Atsumi T, Kato EH, Shimada S, Morikawa M, Minakami H. Prevalence of diverse antiphospholipid antibodies in women with recurrent spontaneous abortion. Fertil Steril 2003; 80: 1276-1278.
56. Bertolaccini ML, Sanna G, Ralhan S et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost 2003; 90: 636-641.
57. Arai T, Matsubayashi H, Sugi T et al. Anti-annexin A5 antibodies in reproductive failures in relation to antiphospholipid antibodies and phosphatidylserine. Am J Reprod Immunol 2003; 50: 202-208.
58. Zanon E, Saggiorato G, Ramon R, Girolami A, Pagnan A, Prandoni P. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost 2004; 91: 255-258.
59. Amoroso A, Mitterhofer AP, Del Porto F et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003; 64: 265-273
60. Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J Thromb Haemost 2003; 1: 718-724.
61. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and anti-beta2-glycoprotem I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003; 62: 540-543.
62. Sanmarco M, Alessi MC, Harle JR et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001; 85: 800-805.
63. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus 2002; 11: 4-10.
64. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121: 142-149.
65. Nojima J, Kuratsune H, Suehisa E et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47: 1008-1015.
66. Aguirre V, Cuchacovich R, Barria L et al. Prevalence and isotype distribution of antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus (SLE). Lupus 2001; 10: 75-80.
67. Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk? Curr Rheumatol Rep 2001; 3: 271-276.
68. Sebastiani GD, Galeazzi M, Tincani A et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28: 344-351.
69. Diri E, Cucurull E, Gharavi AE et al. Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Lupus 1999; 8: 263-268.
70. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythe-matosus. Am J Med Sci 1999; 318: 55-60.
71. Galli M. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Haemostasis 2000; 30(Suppl 2): 57-62.
72. Ulcova-Gallova Z, Bouse V, Krizanovska K et al. Beta 2-glycoprotein I is a good indicator of certain adverse pregnancy conditions. J Fertil Womens Med 2001; 46: 304-308.
73. Song KS, Park YS, Kim HK. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43: 557-560.
74. Erkan D, Zhang HW, Shriky RC, Merrill JT. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002; 11: 215-220.
75. Nojima J, Kuratsune H, Suehisa E et al. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Thromb Haemost 2002; 88: 716-722.
76. Nojima J, Kuratsune H, Suehisa E et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114: 647-654.